ABCA1 and Nephropathy: R3R-01 (also named R3R01, RG-7273) is a specific ABCA1 agonist and entered into phase 2 clinical trials by River 3 Renal Corp. R3R-01 increases ABCA1 expression and may reduce kidney damage by reducing fat levels in the kidney (NephCure, 2024; Reiterova and Tesar, 2023).